Novartis AG (XSWX:NOVNEE) Cyclically Adjusted PB Ratio: (As of Jul. 30, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:NOVNEE Novartis AG XSWX:NOVNEE
80 GF Score
Price CHF119.30
GF Value CHF97.06
! 7 Warning Signs
View Full Analysis

What is Novartis AG Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Novartis AG  (XSWX:NOVNEE) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Novartis AG Cyclically Adjusted PB Ratio Related Terms


Novartis AG Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Novartis AG's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Cyclically Adjusted PB Ratio Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.79 2.81 3.04 3.28 4.29

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.63 3.84 4.29 4.77 5.05

XSWX:NOVNEE vs LLY, JNJ, ABBV: Cyclically Adjusted PB Ratio Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Novartis AG's Cyclically Adjusted PB Ratio falls into.


XSWX:NOVNEE
80GF Score
Novartis AG XSWX:NOVNEE
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Novartis AG's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Novartis AG's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=17.401/108.5400*108.5400
=17.401

Current CPI (Jun. 2026) = 108.5400.

Novartis AG Quarterly Data

Book Value per Share CPI Adj_Book
201609 30.720 99.604 33.476
201612 32.132 99.380 35.094
201703 28.613 100.040 31.044
201706 28.891 100.285 31.269
201709 30.033 100.254 32.515
201712 31.588 100.213 34.213
201803 28.917 100.836 31.126
201806 32.753 101.435 35.047
201809 32.670 101.246 35.024
201812 33.739 100.906 36.292
201903 20.343 101.571 21.739
201906 22.170 102.044 23.581
201909 22.975 101.396 24.594
201912 24.066 101.063 25.846
202003 21.336 101.048 22.918
202006 22.364 100.743 24.095
202009 21.916 100.585 23.649
202012 22.280 100.241 24.125
202103 20.924 100.800 22.531
202106 21.933 101.352 23.488
202109 23.418 101.533 25.034
202112 27.880 101.776 29.733
202203 25.850 103.205 27.186
202206 27.969 104.783 28.972
202209 27.520 104.835 28.493
202212 26.082 104.666 27.047
202303 22.976 106.245 23.472
202306 22.571 106.576 22.987
202309 16.703 106.570 17.012
202312 19.744 106.461 20.130
202403 17.279 107.355 17.470
202406 18.424 107.991 18.518
202409 18.356 107.468 18.539
202412 19.883 107.128 20.145
202503 17.304 107.722 17.435
202506 17.637 108.075 17.713
202509 18.392 107.710 18.534
202512 19.265 107.200 19.506
202603 15.890 108.060 15.961
202606 17.401 108.540 17.401

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Novartis AG (XSWX:NOVNEE) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of CHF119.30 is trading 22.9% above its estimated GF Value™ of CHF97.06.

Key valuation signals for XSWX:NOVNEE:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: CHF97.06 vs. price of CHF119.30 (22.9% above fair value)
  • GF Score™: 80/100 with 7 warning signs

No single metric tells the full story. See the XSWX:NOVNEE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
80GF Score

Get the complete analysis for XSWX:NOVNEE

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF119.30
Price
CHF97.06
GF Value